## Wenkui Li

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2884109/publications.pdf

Version: 2024-02-01

434195 623734 1,371 33 14 31 citations h-index g-index papers 71 71 71 1321 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Dried blood spot sampling in combination with LCâ€MS/MS for quantitative analysis of small molecules. Biomedical Chromatography, 2010, 24, 49-65.	1.7	518
2	Strategies in quantitative LCâ€MS/MS analysis of unstable small molecules in biological matrices. Biomedical Chromatography, 2011, 25, 258-277.	1.7	117
3	Application of LC–MS for quantitative analysis and metabolite identification of therapeutic oligonucleotides. Journal of Pharmaceutical and Biomedical Analysis, 2007, 44, 330-341.	2.8	99
4	Simultaneous determination of norethindrone and ethinyl estradiol in human plasma by high performance liquid chromatography with tandem mass spectrometry—experiences on developing a highly selective method using derivatization reagent for enhancing sensitivity. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 825, 223-232.	2.3	79
5	Implementing Dried Blood Spot Sampling for Clinical Pharmacokinetic Determinations: Considerations from the IQ Consortium Microsampling Working Group. AAPS Journal, 2015, 17, 292-300.	4.4	56
6	Quantitative determination of BAF312, a S1P-R modulator, in human urine by LC–MS/MS: Prevention and recovery of lost analyte due to container surface adsorption. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 583-589.	2.3	46
7	Hydrophilic interaction liquid chromatographic tandem mass spectrometric determination of atenolol in human plasma. Biomedical Chromatography, 2005, 19, 385-393.	1.7	42
8	Liquid chromatographic-electrospray tandem mass spectrometric determination of clarithromycin in human plasma. Biomedical Chromatography, 2006, 20, 1242-1251.	1.7	29
9	Simultaneous determination of ribavirin and ribavirin base in monkey plasma by high performance liquid chromatography with tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 846, 57-68.	2.3	26
10	Supported liquid extraction in combination with LCâ€MS/MS for highâ€throughput quantitative analysis of hydrocortisone in mouse serum. Biomedical Chromatography, 2010, 24, 632-638.	1.7	26
11	Developing a robust ultrafiltration-LC–MS/MS method for quantitative analysis of unbound vadimezan (ASA404) in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 1927-1933.	2.3	26
12	Simultaneous LC–MS/MS quantitation of acetaminophen and its glucuronide and sulfate metabolites in human dried blood spot samples collected by subjects in a pilot clinical study. Bioanalysis, 2012, 4, 1429-1443.	1.5	26
13	Evaluation of plasma microsampling for dried plasma spots (DPS) in quantitative LC-MS/MS bioanalysis using ritonavir as a model compound. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 991, 46-52.	2.3	18
14	Simultaneous determination of midazolam and $1\hat{a}\in^2$ -hydroxymidazolam in human plasma by liquid chromatography with tandem mass spectrometry. Biomedical Chromatography, 2007, 21, 841-851.	1.7	17
15	LC–MS/MS determination of a human mAb drug candidate in rat serum using an isotopically labeled universal mAb internal standard. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1044-1045, 166-176.	2.3	14
16	Quantitative analysis of NIM811, a cyclophilin inhibitor, in human dried blood spots using liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2376-2382.	2.3	13
17	Quantitative analysis of pasireotide (SOM230), a cyclic peptide, in monkey plasma using liquid chromatography in combination with tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1008, 242-249.	2.3	12
18	Evaluation, identification and impact assessment of abnormalÂinternal standardÂresponse variability in regulated LCâ°'MS bioanalysis. Bioanalysis, 2020, 12, 545-559.	1.5	12

#	Article	IF	Citations
19	An investigation of incurred human urine sample reanalysis failure. Bioanalysis, 2011, 3, 967-972.	1.5	10
20	Determination of N-methyl-4-isoleucine-cyclosporin (NIM811) in human whole blood by high performance liquid chromatography-tandem mass spectrometry. Biomedical Chromatography, 2007, 21, 249-256.	1.7	8
21	Highly selective and sensitive LC-MS/MS quantification of a therapeutic protein in human serum using immunoaffinity capture enrichment. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1100-1101, 83-90.	2.3	7
22	A semi-automated LCâ $\in$ "MS/MS method for the determination of LCl699, a steroid $11\hat{l}^2$ -hydroxylase inhibitor, in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 960, 182-193.	2.3	6
23	Quantitative analysis of factor P (Properdin) in monkey serum using immunoaffinity capturing in combination with LC–MS/MS. Bioanalysis, 2016, 8, 425-438.	1.5	6
24	LC–MS/MS bioanalysis of loratadine (Claritin) in dried blood spot (DBS) samples collected by subjects in a clinical research study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 983-984, 117-124.	2.3	5
25	Practical Approaches to Incurred Sample LC-MS/MS Reanalysis: Confirming Unexpected Results. Analytical Chemistry, 2013, 85, 2405-2413.	6.5	4
26	Clinical Exposure Boost Predictions by Integrating Cytochrome P450 3A4–Humanized Mouse Studies With PBPK Modeling. Journal of Pharmaceutical Sciences, 2016, 105, 1398-1404.	3.3	4
27	Quantitative analysis of clofazimine (Lamprene®), an antileprosy agent, in human dried blood spots using liquid chromatography–tandem mass spectrometry. Biomedical Chromatography, 2018, 32, e4068.	1.7	4
28	An industry perspective on tiered approach to the investigation of metabolites in drug development. Bioanalysis, 2014, 6, 617-628.	1.5	2
29	Application of tail vein serial microsampling for plasma or dried plasma spots in toxicokinetic assessment in rats using acetaminophen as the model compound. Biomedical Chromatography, 2020, 34, e4917.	1.7	2
30	Sensitive LC-MS/MS quantification of unconjugated maytansinoid DM4 and its metabolite S-methyl-DM4 in human plasma. Bioanalysis, 2022, 14, 357-368.	1.5	2
31	Critical considerations of matrix selection in LC–MS bioanalysis for toxicokinetic and pharmacokinetic assessment in drug development. Bioanalysis, 2021, 13, 605-608.	1.5	1
32	An integrated outsourcing practice of nonclinical LC–MS bioanalysis and toxicokinetics at Novartis small molecule drug development. Bioanalysis, 2021, 13, 1001-1010.	1.5	1
33	Dixon's Q-test and Student's t-test to assess analog internal standard response in nonregulated LC–MS/MS bioanalysis. Bioanalysis, 2020, 12, 1535-1543.	1.5	1